ஹீமாட்டாலஜி ஆண்டு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஹீமாட்டாலஜி ஆண்டு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஹீமாட்டாலஜி ஆண்டு Today - Breaking & Trending Today

Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma

Eighteen-month follow-up data from pivotal CARTITUDE-1 study, including progression-free-survival data, to be presented at ASCO and EHA Annual Meetings Findings from the Phase 2 CARTITUDE-2 study ....

United States , Ciltacabtagene Autoleucel , Noah Reymond , Jennifer Mcintyre , Saadz Usmani , Christopher Delorefice , Sen Zhuang , Edmond Chan , Hematology Am Soc Hematol Educ Program , National Cancer Institute , Janssen Biotech Inc , American Society Of Clinical Oncology , American Society Of Hematology Annual Meeting , European Hematology Association , Janssen Research Development , Congress Abstract , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Levine Cancer Institute , Clinical Research , American Cancer Society , None Of The Janssen Pharmaceutical Companies , Exchange Commission , Companies Of Johnson , European Medicines Agency Seeking Approval , European Medicines Agency ,

Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®

Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®
- For Use of Subcutaneous Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (D-VCd) in Newly Diagnosed Adult Patients with Systemic Light Chain (AL) Amyloidosis -
- For Use of Subcutaneous Daratumumab in Combination with Pomalidomide and Dexamethasone (D-Pd) in Adult Patients with Relapsed or Refractory Multiple Myeloma -
News provided by
Share this article
Share this article
SAN DIEGO, May 21, 2021 /PRNewswire/ Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Pharmaceutica N.V. (Janssen) received two positive opinions from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending to broaden the existing marketing authorization for the DARZALEX ....

San Diego , United States , Al Kildani , Helen Torley , Bristol Myers Squibb , Janssen Pharmaceutica , American Society Of Hematology Annual Meeting , European Commission , Halozyme Therapeutics Inc , Exchange Commission , Corporate Communications , European Medicines Agency , Committee For Medicinal Products Human Use , European Myeloma Network , Halozyme Therapeutics , Medicinal Products , Human Use , European Myeloma , Quarterly Reports , Absolute Involved Free Light Chain , Difference Between Involved , Uninvolved Free Light Chain Is Associated , Newly Diagnosed , Receiving Bortezomib , Dexamethasone With , Without Daratumumab ,

Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®

Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

San Diego , United States , Al Kildani , Helen Torley , Bristol Myers Squibb , Janssen Pharmaceutica , American Society Of Hematology Annual Meeting , European Commission , Halozyme Therapeutics Inc , Exchange Commission , Corporate Communications , European Medicines Agency , Committee For Medicinal Products Human Use , European Myeloma Network , Halozyme Therapeutics , Medicinal Products , Human Use , European Myeloma , Quarterly Reports , Absolute Involved Free Light Chain , Difference Between Involved , Uninvolved Free Light Chain Is Associated , Newly Diagnosed , Receiving Bortezomib , Dexamethasone With , Without Daratumumab ,

Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX? (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe

Janssen Receives Two Positive CHMP Opinions Recommending Expanded Use of DARZALEX? (daratumumab) Subcutaneous (SC) Formulation for New Indications in Europe
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , United Kingdom , Craig Tendler , Daratumumab Pomalidomide , Christopher Delorefice , Velcade Melphalan , Bortezomib Melphalan , Jennifer Mcintyre , Noah Reymond , Velcade Bortezomib Melphalan , Global Medical Affairs , Janssen Biotech Inc , American Society Of Hematology Annual Meeting , American Society Of Clinical Oncology , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , American Society Of Hematology , European Union , Amyloidosis Research Consortium , National Library Of Medicine , Committee For Medicinal Products Human Use , International Myeloma Workshop Consensus Panel , European Myeloma Network , American Cancer Society , Clinical Development ,

Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma

(1)
Application based on positive Phase 1b/2 data from the CARTITUDE-1 study and follows confirmation of accelerated assessment by the Committee for Medicinal Products for Human Use of the European Medicines Agency
The Janssen Pharmaceutical Companies of Johnson Johnson announced today that they have submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma.
The application is supported by positive results from the ongoing Phase 1b/2 CARTITUDE-1 study, investigating the safety and efficacy of cilta-cel. ....

United States , United Kingdom , Ciltacabtagene Autoleucel , Noah Reymond , Jennifer Mcintyre , Ciltacabtagene Autoleucel Cilta Cel , Christopher Delorefice , Peter Lebowitz , Mathai Mammen , Hematology Am Soc Hematol Educ Program , American Society Of Clinical Oncology , National Cancer Institute , International Myeloma Working Group , Janssen Biotech Inc , American Society Of Hematology Annual Meeting , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Janssen Research Development , American Society Of Hematology , American Cancer Society , None Of The Janssen Pharmaceutical Companies , Regulatory Affairs , European Commission , Drug Administration , Exchange Commission , Companies Of Johnson ,